Motilin

Motilin is a 22-amino-acid linear peptide hormone secreted by specialized enteroendocrine cells (Mo cells) in the mucosal epithelium of the duodenum and proximal jejunum. It is the primary hormonal regulator of the migrating motor complex (MMC), the cyclical pattern of gastrointestinal contractile activity that occurs during fasting to clear residual food, secretions, and cellular debris from the upper GI tract — often described as the gut's "housekeeper." Motilin acts through the motilin receptor (also known as GPR38), a G-protein-coupled receptor expressed on smooth muscle cells, enteric neurons, and enterochromaffin cells of the gastrointestinal tract.

Overview

Motilin was first isolated from porcine duodenal mucosa in 1971 by Brown et al. and subsequently characterized as a key regulator of interdigestive gastrointestinal motility. During fasting, motilin is released in a cyclical pattern with a periodicity of approximately 90-120 minutes, corresponding to Phase III of the MMC — the intense burst of propagating contractions that sweeps aborally from the stomach through the small intestine. This cyclical release is regulated by a complex interplay between enteric nervous system activity, duodenal pH, bile acid exposure, and neural inputs.

The MMC serves critical housekeeping functions: it clears undigested food residues, prevents bacterial overgrowth in the upper small intestine, and propels bile and pancreatic secretions toward the colon. Disruption of the MMC is associated with small intestinal bacterial overgrowth (SIBO), gastroparesis, and functional dyspepsia. Motilin's central role in MMC regulation has made the motilin receptor a primary target for prokinetic drug development.

The discovery that erythromycin, a widely used macrolide antibiotic, stimulates gastrointestinal motility through direct agonism of the motilin receptor was a landmark finding. This explained the well-known "side effect" of GI disturbance with erythromycin therapy and opened a new therapeutic avenue. Erythromycin at sub-antimicrobial doses (40-250 mg) remains the most effective prokinetic available for accelerating gastric emptying, though its use is limited by tachyphylaxis (receptor desensitization within days), QT prolongation risk, antibiotic resistance concerns, and drug interactions.

Motilin biology is notably species-specific. Rodents lack a functional motilin gene and do not have motilin-driven MMC activity, which has hampered preclinical research and necessitated the use of dogs, rabbits, or primates for motilin studies. This species limitation has slowed development of motilin-based therapeutics compared to other GI peptide targets.

Mechanism of Action

Motilin exerts its prokinetic effects through binding to the motilin receptor (MLNR, also designated GPR38), a Gq/11-coupled GPCR:

Phase III MMC Initiation: Motilin is released from Mo cells in cyclical peaks that correspond to the initiation of Phase III contractions of the MMC. The release is driven by a combination of enteric neural reflexes, luminal stimuli (alkaline pH, bile acids), and intrinsic oscillatory activity of Mo cells. Plasma motilin peaks precede the onset of Phase III gastric contractions by several minutes, consistent with a hormonal trigger role. Vantrappen G et al. (1979) — J. Clin. Invest. 63, 1268-1276.

Gastric Smooth Muscle Contraction: Motilin receptor activation on gastric antral smooth muscle cells triggers Gq-mediated phospholipase C activation, IP3-dependent calcium release from the sarcoplasmic reticulum, and calcium/calmodulin-dependent smooth muscle contraction. This pathway directly stimulates antral contractions that initiate gastric emptying of residual contents during fasting.

Enteric Nervous System: Motilin receptors are expressed on cholinergic neurons of the myenteric plexus. Motilin activates these neurons to release acetylcholine, which amplifies the contractile response through muscarinic receptors on smooth muscle. This neural component is important for the coordinated propagation of Phase III contractions — blocking cholinergic transmission with atropine attenuates but does not abolish motilin's motor effects.

Erythromycin as Motilin Agonist: Erythromycin and related 14-membered-ring macrolides directly bind and activate the motilin receptor. The binding site on the motilin receptor for erythromycin overlaps with but is not identical to the motilin binding site, allowing for structural optimization of motilide compounds. Erythromycin's prokinetic potency is comparable to motilin itself at sub-antimicrobial doses, but the therapeutic window is limited by rapid tachyphylaxis (downregulation of motilin receptor expression within 3-5 days of continuous exposure). Peeters TL (1993) — Gastroenterology 105, 1886-1899.

Receptor Desensitization: A major challenge for motilin-based therapeutics is rapid receptor desensitization. Continuous or repeated agonist exposure leads to motilin receptor internalization and downregulation, resulting in loss of prokinetic efficacy (tachyphylaxis). This is observed clinically with erythromycin, where prokinetic effects diminish after 3-4 weeks of continuous use. Strategies to overcome tachyphylaxis include intermittent dosing, partial agonists, and allosteric modulators.

Enterochromaffin Cell Effects: Motilin receptors on enterochromaffin cells stimulate serotonin (5-HT) release, which contributes to the prokinetic response through 5-HT3 and 5-HT4 receptor activation on enteric neurons and smooth muscle. This serotonergic component links motilin signaling to the broader enteric serotonin system.

Reconstitution Calculator

Research

Safety Profile

Motilin itself has not been developed as a therapeutic agent due to its very short half-life (~5 minutes) and peptide nature. Safety considerations primarily apply to motilin receptor agonists, particularly erythromycin used at prokinetic doses. Erythromycin's prokinetic adverse effects include abdominal cramping, nausea (paradoxically), and diarrhea at higher doses. The most significant safety concerns are QT prolongation (dose-dependent, increased risk with co-administration of CYP3A4 inhibitors), promotion of antibiotic resistance when used at antimicrobial doses, and drug interactions through CYP3A4 inhibition. Tachyphylaxis limits long-term efficacy and necessitates drug holidays or intermittent dosing strategies. Non-antibiotic motilides in clinical development have generally been well tolerated but have not overcome the tachyphylaxis challenge. Motilin receptor agonists should be used with caution in patients receiving QT-prolonging medications, those with hepatic impairment (reduced erythromycin clearance), and in settings where antibiotic stewardship is a concern.

Pharmacokinetic Profile